We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+50.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$1.1B
AUM Growth
+$345M
Cap. Flow
+$47.4M
Cap. Flow %
4.29%
Top 10 Hldgs %
64.76%
Holding
67
New
13
Increased
15
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$29.8M
2
IMMX icon
Immix Biopharma
IMMX
+$21.8M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$14.2M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$14.1M
5
VSTM icon
Verastem
VSTM
+$8.71M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$19.5M
2
HROW icon
Harrow
HROW
+$16.1M
3
SNWV
SANUWAVE Health Inc
SNWV
+$10.5M
4
JBIO
Jade Biosciences
JBIO
+$5.89M
5
LQDA icon
Liquidia Corp
LQDA
+$5.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$6.06B
$195M 17.67%
2,447,500
-97,500
-4% -$5.23M
ETON icon
2
Eton Pharmaceutcials
ETON
$1.71B
$104M 9.38%
2,860,000
– –
HROW icon
3
Harrow
HROW
$1.4B
$102M 9.23%
2,400,000
-432,230
-15% -$16.1M
IRON icon
4
Disc Medicine
IRON
$3.07B
$62.5M 5.66%
855,000
+434,000
+103% +$29.8M
URGN icon
5
UroGen Pharma
URGN
$2.13B
$53M 4.8%
1,439,996
+9,996
+0.7% +$271K
APGE icon
6
Apogee Therapeutics
APGE
$10.2B
$51.8M 4.69%
390,000
– –
MGTX icon
7
MeiraGTx Holdings
MGTX
$1.33B
$48M 4.34%
3,550,000
+1,426,741
+67% +$14.2M
SLGL icon
8
Sol-Gel Technologies
SLGL
$225M
$37.1M 3.36%
500,000
– –
RZLT icon
9
Rezolute
RZLT
$445M
$32.8M 2.97%
6,300,000
– –
TGTX icon
10
TG Therapeutics
TGTX
$8.26B
$29.4M 2.66%
535,000
– –
IMMX icon
11
Immix Biopharma
IMMX
$992M
$24.2M 2.19%
+2,345,000
New +$21.8M
CBIO
12
Crescent Biopharma
CBIO
$659M
$23.7M 2.15%
1,319,351
+6,736
+0.5% +$132K
STOK icon
13
Stoke Therapeutics
STOK
$2.04B
$22.9M 2.07%
700,000
– –
ACOG
14
Alpha Cognition
ACOG
$199M
$20.9M 1.89%
2,895,467
+333,517
+13% +$2.09M
EWTX icon
15
Edgewise Therapeutics
EWTX
$4.64B
$20.3M 1.84%
500,000
– –
RVMD icon
16
Revolution Medicines
RVMD
$44.6B
$18.7M 1.7%
100,000
– –
GLUE icon
17
Monte Rosa Therapeutics
GLUE
$1.14B
$18M 1.63%
+745,000
New +$14.1M
ALMS
18
Alumis Inc
ALMS
$2.9B
$15.5M 1.4%
550,000
– –
CDXS icon
19
Codexis
CDXS
$174M
$15.3M 1.39%
6,785,000
– –
REPL icon
20
Replimune Group
REPL
$1.46B
$15.3M 1.39%
+1,384,993
New +$8.47M
XOMA
21
DELISTED
Xoma
XOMA
$14.4M 1.3%
338,374
+38,374
+13% +$1.56M
MBX
22
MBX Biosciences
MBX
$3.03B
$14.4M 1.3%
260,000
– –
RYTM icon
23
Rhythm Pharmaceuticals
RYTM
$7.38B
$13.6M 1.23%
122,500
-500
-0.4% -$45.2K
EDIT icon
24
Editas Medicine
EDIT
$485M
$12.5M 1.13%
3,861,930
+1,934,933
+100% +$5.66M
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.34B
$12.3M 1.11%
100,000
– –
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2026 Portfolio in Review

As of Q2 2026, Opaleye Management held 67 positions worth $1.1B, up 45% from $759M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Opaleye Management deployed $47.4M of net new capital in Q2 2026, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Immix Biopharma: 2,345,000 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Harrow, an estimated $16.1M trimmed.

  • Opaleye Management's largest Q2 2026 buy was Immix Biopharma: 2,345,000 shares worth $24.2M.
  • Opaleye Management added most to Disc Medicine in Q2 2026, an estimated $29.8M increase.
  • Opaleye Management's biggest Q2 2026 reduction was Harrow, cutting an estimated $16.1M.
  • Opaleye Management fully exited Perspective Therapeutics in Q2 2026, selling an estimated $19.5M.
  • Opaleye Management's ten largest holdings make up 65% of its $1.1B portfolio in Q2 2026.
  • Opaleye Management opened 13 new positions and closed 9 in Q2 2026.
  • Opaleye Management's portfolio value rose 45% quarter-over-quarter to $1.1B.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.